David Morris, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    UroGen Pharma
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Taris Biomedical
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    UroGPO
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Tolmar
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Decipher Bio
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    GenomeDx
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Invitae
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck
    Date added:
    Date updated:
    05/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    05/24/2024

Pages

Return to PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community Webcast (2021)